Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Insider Sells $208,391.04 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider owned 20,422 shares of the company’s stock, valued at $593,054.88. The trade was a 26.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.58, for a total value of $54,891.10.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK traded up $0.26 on Wednesday, reaching $31.93. 634,783 shares of the company traded hands, compared to its average volume of 753,262. The company’s 50 day moving average is $30.40 and its 200-day moving average is $32.01. The stock has a market capitalization of $1.99 billion, a PE ratio of -11.36 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $12.75 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.09%. As a group, analysts expect that Stoke Therapeutics, Inc. will post -3.22 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on STOK shares. Wedbush boosted their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group dropped their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Finally, The Goldman Sachs Group assumed coverage on Stoke Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $44.00 target price on the stock. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its stake in shares of Stoke Therapeutics by 333.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after buying an additional 1,116,452 shares during the period. State Street Corp increased its stake in shares of Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares during the last quarter. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics in the second quarter worth $7,489,000. Troluce Capital Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter worth $21,255,000. Finally, BVF Inc. IL raised its holdings in shares of Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after acquiring an additional 608,578 shares in the last quarter.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Stoke outlined plans to submit a rolling New Drug Application (NDA) for zorevunersen in the first quarter of 2027, with a potential U.S. launch by early 2028. Management said its approximately $420 million in cash supports development and launch preparations, reducing near-term financing concerns. Stoke outlines rolling NDA in Q1 2027
• Positive Sentiment: Second-quarter revenue of roughly $9.3 million substantially exceeded the $4.89 million analyst consensus, despite the company remaining unprofitable. The earnings call and business update highlighted continued progress in Stoke’s Dravet syndrome program. Second-quarter 2026 financial results
• Positive Sentiment: Analyst support remains strong. Guggenheim reaffirmed a Buy rating with a $60 price target, while Wedbush maintained Outperform and raised its target to $40. Chardan also reiterated Buy with a $35 target. Analyst ratings
• Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, which could provide additional visibility into its pipeline and regulatory plans but does not represent a new operating update by itself. Canaccord Genuity conference presentation
• Negative Sentiment: Stoke reported a second-quarter loss of $0.93 per share, wider than the approximately $0.80–$0.82 consensus loss and worse than the $0.40 loss a year earlier. HC Wainwright also reduced its FY2029 EPS estimate to $1.55 from $1.63 and FY2030 estimate to $3.56 from $3.74. Second-quarter loss and revenue results

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.